Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2018

01-11-2018 | Original Article

Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana

Authors: Timothée Bonifay, Jean-François Lienne, Cécile Bagoée, Florin Santa, Guillaume Vesin, Gaëlle Walter, Mathieu Nacher, Nathalie Vaserman, Félix Djossou, Loïc Epelboin

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2018

Login to get access

Abstract

The estimated seroprevalence in the general population after chikungunya virus (CHIKV) epidemics ranged from 38 to 63%. Despite a low case fatality, subacute and chronic rheumatic forms of CHIKV infection generate significant morbidity and have a socioeconomic impact. The objective of the study was to estimate the prevalence of chronic post-CHIKV rheumatic or musculoskeletal pain (pCHIK-RMSP) at 3 and 6 months after the initial symptoms. An observational study was conducted at Cayenne General Hospital in French Guiana between April 1 and June 30, 2014. All patients seen for CHIKV infection confirmed by RT-PCR were prospectively included. Pregnant women and children under 15 were excluded from the study. All patients were called by phone at 3 and 6 months to enquire about the presence of pCHIK-RMSP. Out of a total of 254 eligible patients, 168 were selected. The mean age was 45.3 years (SD ± 1.4 yo) and the sex ratio (M/F) was 0.75. No death was reported. At 3 months, 40.2% (95% CI 31.1–49.3) of patients (n = 45/112) had pCHIK-RMSP and 31.3% (95% CI 22.2–40.4) of patients (n = 31/99) at 6 months. The median time of end to pain was 2 weeks after the date of onset of signs. The present study provides succinct but informative data about pCHIK-RMSP, which represents the real burden of the disease. There are few studies on that subject in the Amazonian region, but our study shows a lower impact than in the Indian Ocean islands where the population is older.
Literature
3.
go back to reference Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N et al (2007) Seroprevalence of chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg 76:1189–1193CrossRef Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N et al (2007) Seroprevalence of chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg 76:1189–1193CrossRef
10.
22.
go back to reference Bylon D (1780) Korte Aantekening wegens eene algemeene Ziekte, doorgaans genaamd Knokkel-koorts. Verh Batav Genootsch Konsten En Wet 2:17–30 Bylon D (1780) Korte Aantekening wegens eene algemeene Ziekte, doorgaans genaamd Knokkel-koorts. Verh Batav Genootsch Konsten En Wet 2:17–30
Metadata
Title
Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana
Authors
Timothée Bonifay
Jean-François Lienne
Cécile Bagoée
Florin Santa
Guillaume Vesin
Gaëlle Walter
Mathieu Nacher
Nathalie Vaserman
Félix Djossou
Loïc Epelboin
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3353-0

Other articles of this Issue 11/2018

European Journal of Clinical Microbiology & Infectious Diseases 11/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.